Shares of contraceptive and diagnostic manufacturer Cupid climbed by more than 3% during Friday trading, touching a new 52-week high of Rs 368 each on the National Stock Exchange. The movement marked a fourth consecutive session of positive trading for the company. Across shorter periods, the equity has increased by more than 16% in one week, 30% in one month, and 246% during 2026 so far. Over longer horizons, the counter has achieved gains of 657% in the past twelve months, nearly 8,700% across three years, and exceeding 15,410% over a five-year period.
The sustained market interest coincides with Cupid revising its financial projections upwards twice in under two weeks earlier this month. For the ongoing financial year 2027, the organisation projects total revenue to reach Rs 800 crore alongside a net profit of Rs 250 crore. Operational momentum remains strong during the fiscal period, with second-quarter revenue alone anticipated to exceed Rs 200 crore. Leadership attributed the upgraded guidance to steady operational performance across primary business lines alongside stronger commercial visibility across domestic and global arenas.
Management highlighted several operational milestones behind the upward guidance adjustments. The momentum observed during the second quarter of FY27 is expected to persist and expand throughout the third and fourth quarters. Contributing factors include stronger prospects in institutional and private client markets, continuous progress in domestic fast-moving consumer goods distribution, advancements toward commencing operations at the Palava production site, and continuous gains within the company's healthcare and personal care lines.
Looking forward, Cupid intends to broaden its domestic distribution network by building greater market penetration through pharmacies, general trade, and modern trade channels. The producer also plans to operationalise its Palava manufacturing plant, an asset intended to lift aggregate manufacturing capacity, enhance production adaptability, and support broader delivery capabilities for customers located both inside India and overseas. Furthermore, the company aims to widen its portfolio through fresh product introductions, required regulatory clearances, and expanded commercial sales.
Beyond domestic initiatives, Cupid is targeting foreign healthcare expansion across various institutional, government, and private commercial avenues. The enterprise plans to construct regional production platforms via an intended venture located in South Africa, which is expected to serve as a launchpad for broader international distribution. In parallel, management intends to explore complementary healthcare and personal care alliances, evaluating prospective commercial partnerships and corporate investments to support its existing industrial base.
As an operating entity, Cupid engages in the production and distribution of male condoms, female condoms, water-based lubricating jelly, and in vitro diagnostic test kits. The leadership team links its corporate execution to tapping market possibilities across both domestic consumer channels and institutional tenders, alongside expanding physical production capacity to fulfill rising delivery commitments across these diverse categories.
Key numbers
- Peak share price: Rs 368
- Targeted FY27 revenue: Rs 800 crore
- Targeted FY27 net profit: Rs 250 crore
- Expected Q2 FY27 revenue: over Rs 200 crore
- Five-year stock return: over 15,410%
What a board might note
- How achievable is the revised FY27 revenue target of Rs 800 crore and net profit target of Rs 250 crore given that guidance was altered twice within two weeks?
- What capital expenditure and operational risks are tied to the planned commissioning of the Palava manufacturing facility and the proposed venture in South Africa?
- How dependent is the projected quarterly progression across Q3 and Q4 FY27 on the timely rollout of domestic FMCG distribution across pharmacy and modern trade channels?
Source: Economic Times, 9 October 2026. This is a summary of a news report, published as general information. It is not legal, tax or investment advice.
This article is journalism and commentary. It is not a recommendation to buy or sell any security, and it is not professional advice. Read the full disclaimer.
